OBGYN & Women’s Health

Low-dose acetylsalicylic acid reduces inflammatory protein levels and tissue perfusion in dense breast tissue in postmenopausal women, according to the results of a new phase II clinical trial. High mammographic density is a major risk factor for breast cancer, contributing to approximately 30% of all breast cancer. There is a lack of research regarding the...

DRL-Trastuzumab was found to have similar efficacy, safety, pharmacokinetics, and immunogenicity as Herceptin in HER2-positive breast cancer patients in a randomized, double-blind study. Trastuzumab, marketed under the brand name Herceptin, is a standard therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The drug DRL_TZ, a potential trastuzumab biosimilar to Herceptin, was developed...

A small cohort study found that p53 null mutations confer a particularly severe prognosis in high-grade serous ovarian cancers. Epithelial ovarian cancer is the fifth most common cause of female cancer-related mortality in the developed world. The most frequent type of epithelial ovarian cancer is high-grade serous ovarian cancer (HGSOC).  A cohort study published in...

A cohort study finds that histologic subtype is the main factor associated with survival disparities between Black and White uterine cancer patients. Survival disparities have existed between non-Hispanic Black and White uterine cancer patients for decades, with an increased likelihood of aggressive disease, recurrence, and death among Black patients.  A cohort study published in JAMA...

Gynecological cancer uniquely affects health-related quality of life. A 2023 literature review reports that treatment side effects such as fatigue, pain, and sexual dysfunction impact psychological well-being. Younger patients and those in advanced stages generally experience greater challenges. Tailoring treatment approaches and implementing supportive care can help improve health-related quality of life for survivors. Gynecological...

In a retrospective cohort study, racial disparities in the use of medications and interventions near end of life were observed among patients with advanced gynecologic cancer.  Palliative medicine improves outcomes in patients with gynecologic malignancies. Studies on palliative medicine in cancer have minimal representation from minority groups. A retrospective cohort study published in the journal...

Intermittent relacorilant + nab-paclitaxel improves survival outcomes and response duration in platinum-resistant/refractory ovarian cancer compared to nab-paclitaxel monotherapy, according to the results of a phase II study. Treatment of advanced epithelial ovarian cancer is challenging. Most patients who initially respond to platinum-based chemotherapy eventually develop resistance. Patient outcomes are poor in platinum-resistant/refractory ovarian cancer treated...

Mortality rates generally highest for infants of Black and American Indian and Alaska Native non-Hispanic women There is variation in infant mortality rates across maternal race and Hispanic-origin groups and by selected maternal characteristics, according to the March 5 National Vital Statistics Reports, a publication from the National Center for Health Statistics. Danielle M. Ely, Ph.D.,...

A phase III study suggests that olaparib-bevacizumab is not only effective for high-risk (of relapse) HRD-positive tumors but is even more effective for low-risk patients in prolonging progression-free survival. Cure is the ultimate goal of ovarian cancer treatment; however, ovarian cancer patients are often first diagnosed at advanced stages, with an increased risk of relapse....